Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

animedica gmbh* - butorphanolum tartrat - stungulyf, lausn - 4 mg/ml

Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

le vet beheer b.v. - butorphanolum tartrat - stungulyf, lausn - 10 mg/ml

Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

viatris limited - clomipraminum hýdróklóríð - filmuhúðuð tafla - 25 mg

Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

viatris limited - clomipraminum hýdróklóríð - filmuhúðuð tafla - 10 mg

Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

abcur ab* - methadonum hýdróklóríð - tafla - 40 mg

Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

le vet beheer b.v. - buprenorphinum hýdróklóríð - stungulyf, lausn - 0,3 mg/ml

Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

abcur ab* - methadonum hýdróklóríð - tafla - 20 mg

Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

2care4 generics aps - methadonum hýdróklóríð - tafla - 20 mg

Unione Europea - islandese - EMA (European Medicines Agency)

gilead sciences ireland uc - idelalisib - lymphoma, non-hodgkin; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, other antineoplastic agents - zydelig is indicated in combination with an anti‑cd20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (cll):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies. zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (fl) that is refractory to two prior lines of treatment.

Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

le vet beheer b.v. - methadonum hýdróklóríð - stungulyf, lausn - 10 mg/ml